MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Gilead Sciences Inc.

Deschisă

SectorSănătate

103.29 -3.49

Rezumat

Modificarea prețului

24h

Curent

Minim

100.88

Maxim

107.3

Indicatori cheie

By Trading Economics

Venit

530M

1.8B

Vânzări

29M

7.6B

P/E

Medie Sector

274.553

57.333

EPS

1.9

Randament dividend

3.02

Marjă de profit

23.557

Angajați

17,600

EBITDA

-655M

3.1B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+9.79% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.02%

2.63%

Data viitoare de dividende

26 iun. 2025

Următoarea dată ex-dividende

13 iun. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

8.7B

130B

Deschiderea anterioară

106.78

Închiderea anterioară

103.29

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Gilead Sciences Inc. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2025, 20:17 UTC

Câștiguri

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

11 feb. 2025, 21:17 UTC

Câștiguri

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

24 apr. 2025, 20:08 UTC

Câștiguri

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences 1Q Rev $6.67B >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences 1Q EPS $1.04 >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences 1Q EPS $1.04 >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences Sees FY EPS $5.65-EPS $6.05 >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences 1Q Total Liver Disease Sales $758M >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences 1Q Net $1.32B >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences Sees FY Adj EPS $7.70-Adj EPS $8.10 >GILD

24 apr. 2025, 20:02 UTC

Câștiguri

Gilead Sciences 1Q Rev $6.7B >GILD

11 apr. 2025, 09:30 UTC

Top știri

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

19 mar. 2025, 14:50 UTC

Top știri

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 feb. 2025, 22:13 UTC

Market Talk
Câștiguri

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11 feb. 2025, 21:06 UTC

Câștiguri

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Raises Dividend 2.6%>GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

Comparație

Modificare preț

Gilead Sciences Inc. Așteptări

Obiectiv de preț

By TipRanks

9.79% sus

Prognoză pe 12 luni

Medie 116.79 USD  9.79%

Maxim 140 USD

Minim 89 USD

În baza a 24 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGilead Sciences Inc. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

24 ratings

18

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

105 / 106.5Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Very Strong Bearish Evidence

Termen lung

Weak Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.